A muti-society guidance statement involving the ASA, American Gastroenterological Association (AGA), American Society for Metabolic and Bariatric Surgery (ASMBS), International Society for the Perioperative Care of Patients with Obesity, and Society of American Gastrointestinal and Endoscopic Surgeons [17] reevaluated the risk-benefit balance and concluded that most patients could continue GLP-1 RA prior to elective surgery, emphasizing the need to apply mitigation strategies and to make an individual risk stratification [17-19]. The gene discussed is GLP1R; the disease is obesity disorder.